$1.74
San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.
Our top picks for where to buy Bioatla Inc stock
How to buy BioAtla stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BCAB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy BioAtla stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
BioAtla stock price (NASDAQ: BCAB)
Use our graph to track the performance of BCAB stocks over time.BioAtla shares at a glance
Latest market close | $1.74 |
---|---|
52-week range | $1.14 - $4.02 |
50-day moving average | $1.63 |
200-day moving average | $2.17 |
Wall St. target price | $9.75 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.17 |
Is it a good time to buy BioAtla stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioAtla price performance over time
Historical closes compared with the close of $1.74 from 2024-09-06
1 week (2024-08-30) | -1.69% |
---|---|
1 month (2024-08-07) | 25.18% |
3 months (2024-06-07) | 14.47% |
6 months (2024-03-07) | -38.73% |
1 year (2023-09-07) | -28.69% |
---|---|
2 years (2022-09-07) | -79.74% |
3 years (2021-09-07) | 38.47 |
5 years (2019-09-03) | N/A |
BioAtla financials
Gross profit TTM | $-79,347,000 |
---|---|
Return on assets TTM | -55.38% |
Return on equity TTM | -134.14% |
Profit margin | 0% |
Book value | $0.65 |
Market Capitalization | $85.6 million |
TTM: trailing 12 months
BioAtla share dividends
We're not expecting BioAtla to pay a dividend over the next 12 months.
BioAtla share price volatility
Over the last 12 months, BioAtla's shares have ranged in value from as little as $1.14 up to $4.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioAtla's is 1.048. This would suggest that BioAtla's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put BioAtla's beta into context you can compare it against those of similar companies.
- XBiotech (XBIT.US): 1.379
- Genmab AS (GMAB.US): 0.842
- Mersana Therapeutics (MRSN.US): 1.465
BioAtla overview
BioAtla, Inc. , a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. .
Frequently asked questions
nullWhat percentage of BioAtla is owned by insiders or institutions?
Currently 10.761% of BioAtla shares are held by insiders and 56.047% by institutions. How many people work for BioAtla?
Latest data suggests 65 work at BioAtla. When does the fiscal year end for BioAtla?
BioAtla's fiscal year ends in December. Where is BioAtla based?
BioAtla's address is: 11085 Torreyana Road, San Diego, CA, United States, 92121 What is BioAtla's ISIN number?
BioAtla's international securities identification number is: US09077B1044
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
Ask a question